文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

家族性低尿钙性高钙血症1型母亲后代的新生儿低钙惊厥

Neonatal Hypocalcemic Seizures in Offspring of a Mother With Familial Hypocalciuric Hypercalcemia Type 1 (FHH1).
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本文报道一个三代家族性低尿钙性高钙血症1型(FHH1)家系,其中一名母亲所生4名子女中2名无症状高钙血症、1名血钙正常、1名发生短暂新生儿低钙惊厥,该低钙婴儿血钙1.57 mmol/L(6.28 mg/dL)、甲状旁腺激素2.2 pmol/L,需静脉葡萄糖酸钙治疗;高钙成员携带新型杂合p.Ser448Pro CaSR变异,体外实验证实为功能丧失性突变。

要点

  • FHH1母亲的后代可因遗传的CaSR突变不同而出现高钙血症或短暂新生儿低钙血症。
  • 新生儿低钙惊厥患儿血钙1.57 mmol/L,需静脉葡萄糖酸钙输注治疗。
  • 高钙成员携带新型杂合p.Ser448Pro CaSR变异,体外实验显示其损伤CaSR功能。

核心结论

  • FHH1母亲的后代可发生高钙血症或短暂新生儿低钙血症,取决于所遗传的CaSR突变,并需在幼儿期进行血钙和CaSR突变检查。

研究设计与样本

  • 对一个三代FHH家系在知情同意后进行临床、生化和突变分析。

主要发现

  • 该家系包括一名高钙血症男性及其女儿(高钙血症和低尿钙症)以及她的4名子女,其中2名无症状高钙血症、1名血钙正常、1名发生短暂新生儿低钙血症和惊厥。
  • 低钙婴儿血清钙为1.57 mmol/L(6.28 mg/dL;正常2.0-2.8 mmol/L,8.0-11.2 mg/dL),甲状旁腺激素为2.2 pmol/L(正常1.0-9.3 pmol/L),需要静脉葡萄糖酸钙输注治疗。
  • 在高钙个体中鉴定出新型杂合p.Ser448Pro CaSR变异,而低钙血症或血钙正常的子女中未发现该变异。
  • 三维建模预测p.Ser448Pro变异破坏CaSR胞外域内的氢键相互作用;在HEK293细胞中表达时,Pro448 CaSR显著削弱细胞外钙刺激后的CaSR介导的细胞内钙动员和丝裂原活化蛋白激酶反应,证明其为功能丧失性突变。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Familial hypocalciuric hypercalcemia type 1 (FHH1) is caused by loss-of-function mutations of the calcium-sensing receptor (CaSR) and is considered a benign condition associated with mild-to-moderate hypercalcemia. However, the children of parents with FHH1 can develop a variety of disorders of calcium homeostasis in infancy. OBJECTIVE: The objective of this work is to characterize the range of calcitropic phenotypes in the children of a mother with FHH1. METHODS: A 3-generation FHH kindred was assessed by clinical, biochemical, and mutational analysis following informed consent. RESULTS: The FHH kindred comprised a hypercalcemic man and his daughter who had hypercalcemia and hypocalciuria, and her 4 children, 2 of whom had asymptomatic hypercalcemia, 1 was normocalcemic, and 1 suffered from transient neonatal hypocalcemia and seizures. The hypocalcemic infant had a serum calcium of 1.57 mmol/L (6.28 mg/dL); normal, 2.0 to 2.8 mmol/L (8.0-11.2 mg/dL) and parathyroid hormone of 2.2 pmol/L; normal 1.0 to 9.3 pmol/L, and required treatment with intravenous calcium gluconate infusions. A novel heterozygous p.Ser448Pro CaSR variant was identified in the hypercalcemic individuals, but not the children with hypocalcemia or normocalcemia. Three-dimensional modeling predicted the p.Ser448Pro variant to disrupt a hydrogen bond interaction within the CaSR extracellular domain. The variant Pro448 CaSR, when expressed in HEK293 cells, significantly impaired CaSR-mediated intracellular calcium mobilization and mitogen-activated protein kinase responses following stimulation with extracellular calcium, thereby demonstrating it to represent a loss-of-function mutation. CONCLUSIONS: Thus, children of a mother with FHH1 can develop hypercalcemia or transient neonatal hypocalcemia, depending on the underlying inherited CaSR mutation, and require investigations for serum calcium and CaSR mutations in early childhood.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dharmaraj P, Gorvin CM, Soni A, et al. Neonatal Hypocalcemic Seizures in Offspring of a Mother With Familial Hypocalciuric Hypercalcemia Type 1 (FHH1). J Clin Endocrinol Metab. 2020. PMID: 32150253. doi:10.1210/clinem/dgaa111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。